Salix Commences Cash Tender Offer for Outstanding Shares of Santarus at $32.00/Share

- Salix Pharmaceuticals, Ltd. SLXP today announced the commencement of a cash tender offer by its indirect wholly owned subsidiary, Willow Acquisition Sub Corporation (“Purchaser”), to purchase all of the issued and outstanding shares of common stock, par value $0.0001 per share, of Santarus, Inc. SNTS (“Santarus”) at a purchase price of $32.00 per share, net to the seller in cash, without interest and subject to any required withholding taxes. The tender offer is being made pursuant to an Offer to Purchase, dated December 3, 2013, and in connection with the previously announced definitive merger agreement, dated November 7, 2013, among Salix, Salix Pharmaceuticals, Inc., a wholly owned subsidiary of Salix (“Intermediary”), Purchaser and Santarus. See full press release
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsGuidanceContractsManagementM&AGlobal
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!